Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Y.
Right arrow Articles by Sarkar, F. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.
Right arrow Articles by Sarkar, F. H.
[Cancer Research 65, 3877-3882, May 1, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Epidermal Growth Factor Receptor–Related Protein Inhibits Cell Growth and Induces Apoptosis of BxPC3 Pancreatic Cancer Cells

Yuxiang Zhang1, Sanjeev Banerjee1, Zhi-wei Wang1, Dorota J. Marciniak2, Adhip P.N. Majumdar2 and Fazlul H. Sarkar1

1 Department of Pathology, Karmanos Cancer Institute and 2 Department of Internal Medicine, Wayne State University School of Medicine, Veterans Affairs Medical Center, Detroit, Michigan

Requests for reprints: Fazlul H. Sarkar, Department of Pathology, Wayne State University School of Medicine, 715 Hudson-Webber Cancer Research Center, 110 East Warren Avenue, Detroit, MI 48201. Phone: 313-966-7279; Fax: 313-966-7558; E-mail: fsarkar{at}med.wayne.edu.

Dysregulation of the epidermal growth factor receptor (EGFR) signaling network has been frequently reported in pancreatic cancer. Inhibition of EGFR was associated with antitumor effects in both in vitro and in vivo studies of pancreatic cancer. We have previously reported the isolation and characterization of an EGFR-related protein (ERRP), which seems to be a negative regulator of EGFR. In the present investigation, we tested our hypothesis whether recombinant ERRP could be an effective inhibitor of growth of BxPC3 pancreatic cancer cells. Cell growth and apoptosis were measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and apoptosis ELISA assay, respectively, in the presence and absence of recombinant ERRP in BxPC3 cells. To evaluate activation of EGFR and its downstream signaling events, levels of phospho-EGFR, phospho-AKT, and phospho-extracellular signal-regulated kinase (phospho-ERK) were determined by Western blot analysis. NF-{kappa}B activity was measured by electrophoretic mobility shift assay. Our data show, for the first time, that ERRP inhibits the growth of BxPC3 cells in a dose- and time-dependent manner. The EGF or transforming growth factor (TGF)-{alpha}–induced stimulation of cell growth and activation of EGFR was also inhibited by ERRP. These changes were accompanied by a concomitant attenuation of activation of mitogen-activated protein (MAP) kinases, AKT, and NF-{kappa}B. ERRP also induced apoptosis as evidenced by increased poly(ADP-ribose) polymerase cleavage and reduction in procaspase3. From these results, we conclude that ERRP is a potent inhibitor of growth of BxPC-3 pancreatic cancer cells, which could be due to attenuation of EGFR cellular signaling processes. We also suggest that ERRP could be a potential therapeutic agent for pancreatic cancer.




This article has been cited by other articles:


Home page
Cancer Res.Home page
E. M. Schmelz, H. Xu, R. Sengupta, J. Du, S. Banerjee, F. H. Sarkar, A. K. Rishi, and A. P.N. Majumdar
Regression of Early and Intermediate Stages of Colon Cancer by Targeting Multiple Members of the EGFR Family with EGFR-Related Protein
Cancer Res., June 1, 2007; 67(11): 5389 - 5396.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Wang, R. Sengupta, S. Banerjee, Y. Li, Y. Zhang, K.M. W. Rahman, A. Aboukameel, R. Mohammad, A. P.N. Majumdar, J. L. Abbruzzese, et al.
Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer.
Cancer Res., August 1, 2006; 66(15): 7653 - 7660.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Z. Wang, Y. Zhang, Y. Li, S. Banerjee, J. Liao, and F. H. Sarkar
Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells.
Mol. Cancer Ther., March 1, 2006; 5(3): 483 - 493.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Zhang, S. Banerjee, Z. Wang, H. Xu, L. Zhang, R. Mohammad, A. Aboukameel, N. V. Adsay, M. Che, J. L. Abbruzzese, et al.
Antitumor Activity of Epidermal Growth Factor Receptor-Related Protein Is Mediated by Inactivation of ErbB Receptors and Nuclear Factor-{kappa}B in Pancreatic Cancer
Cancer Res., January 15, 2006; 66(2): 1025 - 1032.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.